Menu
An allogeneic first in class immunotherapy harnessing the patient immune system to fight immune tolerance and prevent cancer resistance
Phase I/II 1L mCRC study synopsis validated
Launch in 2025 (US, BEL, FR)
An allogeneic first in class immunotherapy harnessing the patient immune system to fight immune tolerance and prevent cancer resistance
Phase I/II 1L mCRC study synopsis validated
Launch beg early 2024 (US, BEL, FR)
of cancer mortality worldwide
Patients in 2029 WW
of patients treated by chemotherapies in 1L inducing toxicity, resistances, and tumor plasticity.
For Standard of care : Pembrolizumab, Atezolizumab, Nivolumab, Ipilimumab (within 2028)
To meet the need in targeting treatment resistance
To meet the need in breaking immunue tolerance
in colorectal cold and hot mice model
in several model
mice model
To meet the need for an accessible approach
Adapted from C. Cremolini ESMO 2021
GM-CSF low dose: Recruits APC at injection point and mature DCs.
Checkpoint inhibitors, ADC TLR Promotes T cell priming and activation
Chemokyne cytokine TLR : Increase trafficking of T cell
Bevacizumab Facilitates infiltration of CD8+ lymphocytes into tumors
5FU, Bevacizumab and Cyclophosphamide low dose, radiotherapy. Decrease the activity of immunosuppressive cells (Tregs and MDSCs)
Checkpoint inhibitors, ADC, BiSpecific mAb, TLR restores the anticancer immunity
Brenus’ manufacturing process overpasses the lack of immunogenicity & educates the immune system with visible and multi-specific targets
Selection criteria of starting material (Allogeneic tumor cell lines)
Brenus’ manufacturing process overpasses the lack of antigenicity & educates the immune system with a broad & higher quality range of tumor antigens